A randomised phase III trial of adjuvant cemiplimab in patients with resected stage II-IIIA NSCLC who have not received prior adjuvant chemotherapy
The aim of this trial is to determine the efficacy of adjuvant cemiplimab, as measured by disease-free survival, in patients with resected stage II-IIIA NSCLC without prior adjuvant platinum-based chemotherapy, compared to observation without adjuvant treatment. The primary objective will be assessed in patients with tumours with centrally confirmed PD-L1 expression of ≥1%.